Clinical Trial Update: GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection [Phase 2]

View source ↗

Summary

This Phase 2 trial from Gilead evaluated a four-drug regimen including GS-5885 (ledipasvir), GS-9451, tegobuvir, and ribavirin in patients with chronic genotype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GS-5885 (Ledipasvir) (Ledipasvir)
• GS-9451 (GS-9451)
• Ribavirin (ribavirin)
• Tegobuvir (Tegobuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED